Frost & Sullivan Independent Equity Research
Revolutionary technology enables cardiologists to make better decisions and results in 30% assumed revenue growth by the end of 2019; Itamar Medical has a $6.8B addressable market with limited competition; we start our coverage with a price target of 1.51 NIS.
![itamarmedicallargelogo itamarmedicallargelogo](https://www.frostequityresearch.com/wp-content/uploads/elementor/thumbs/itamarmedicallargelogo-od9sme1e29njrnkfpfd06mlz42yfdh17kesxws9ogs.png)
Company: Itamar Medical
Sector: Healthcare
Report type: Initiation Report
Published on: June 26, 2019